Robert Graham G Russell

Robert Graham G Russell

Auto-generated profile, based on publicly available information

Robert Graham G Russell

Department of Oncology and Metabolism, Medical School, University of Sheffield, UK

Research Focus & Metrics

Academic Career Length

63Years (1964-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2008 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
RRR. G. G. Russell
R. G. G. Russell
NWN. B. Watts
N. B. Watts
FEF. H. Ebetino
F. H. Ebetino
MRM. J. Rogers
M. J. Rogers

1 April 1998 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
SLSteven P. Luckman
Steven P. Luckman
DHDavid E. Hughes
David E. Hughes
FCFraser P. Coxon
Fraser P. Coxon
RRR. Graham G. Russell
R. Graham G. Russell
MRMichael J. Dr. Rogers
Michael J. Dr. Rogers
Bisphosphonates are currently the most important class of antiresorptive drugs used for the treatment of metabolic bone diseases. Although the molecular targets of bisphosphonates have not been identified, these compounds inhibit bone resorption by mechanisms that can lead to osteoclast apoptosis. Bisphosphonates also induce apoptosis in mouse J774 macrophages in vitro, probably by the same mechanisms that lead to osteoclast apoptosis. We have found that, in J774 macrophages, nitrogen-containing bisphosphonates (such as alendronate, ibandronate, and risedronate) inhibit post-translational modification (prenylation) of proteins, including the GTP-binding protein Ras, with farnesyl or geranylgeranyl isoprenoid groups. Clodronate did not inhibit protein prenylation. Mevastatin, an inhibitor of 3-hydroxy-3-methylglutatyl (HMG)-CoA reductase and hence the biosynthetic pathway required for the production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, also caused apoptosis in J774 macrophages and murine osteoclasts in vitro. Furthermore, alendronate-induced apoptosis, like mevastatin-induced apoptosis, could be suppressed in J774 cells by the addition of farnesyl pyrophosphate or geranylgeranyl pyrophosphate, while the effect of alendronate on osteoclast number and bone resorption in murine calvariae in vitro could be overcome by the addition of mevalonic acid. These observations suggest that nitrogen-containing bisphosphonate drugs cause apoptosis following inhibition of post-translational prenylation of proteins such as Ras. It is likely that these potent antiresorptive bisphosphonates also inhibit bone resorption by preventing protein prenylation in osteoclasts and that enzymes of the mevalonate pathway or prenyl protein transferases are the molecular targets of the nitrogen-containing bisphosphonates. Furthermore, the data support the view that clodronate acts by a different mechanism.

1 July 2011 in Bone
Verified
Journal Article
Closed access
RRR. Graham G. Russell
R. Graham G. Russell

1 November 1983 in Nature
Verified
Journal Article
Open access
PDF file
MGMaxine Gowen
Maxine Gowen
DWDavid D. Wood
David D. Wood
EIEarl J. Ihrie
Earl J. Ihrie
MMMary K. B. McGuire
Mary K. B. McGuire
RRR. Graham G. Russell
R. Graham G. Russell
Many activities are now ascribed to the monokine interleukin 11 including enhancement of immune responses, stimulation of thymocyte proliferation2, activation of B cells3, stimulation of proteinase and prostaglandin production by connective tissue cells4, stimulation of the production of acute phase proteins5, induction of fever6 and the induction of neutrophilia7. These activities were thought to be due to various different factors, but are now considered probably due to very similar, if not identical, molecules8–11. The term interleukin 1 (IL-1) was coined to describe the factor released by monocyte/macrophages which acts on T and B lymphocytes. Only after this definition had been accepted was it shown that target cells other than lymphocytes were affected by IL-1. Products of human blood monocytes (mononuclear cell factor, MCF) have been implicated in the pathogenesis of inflammatory diseases such as rheumatoid arthritis and periodontal disease12,13. Bone resorption is often a feature of such diseases, and monocytes are frequently found at sites of localized bone resorption. Preliminary experiments with monocyte-conditioned medium indicated that MCF could stimulate bone resorption14. We therefore undertook this study to verify these observations and to determine whether purified IL-1 could stimulate connective tissue breakdown in vitro.

1 May 2006 in Bone
Verified
Journal Article
Closed access
GNG.H. Nancollas
G.H. Nancollas
RTR. Tang
R. Tang
RPR.J. Phipps
R.J. Phipps
ZHZ. Henneman
Z. Henneman
SGS. Gulde
S. Gulde
FEF.H. Ebetino
F.H. Ebetino

1 July 1999 in Bone
Verified
Journal Article
Closed access
RRR.G.G Russell
R.G.G Russell
MRM.J Rogers
M.J Rogers